FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2530998614> ?p ?o ?g. }

• W2530998614 abstract "Abstract In spite of favorable response and survival results for the majority of CML patients on imatinib therapy, in a substantial minority imatinib fails or shows suboptimal responses. A treatment optimization study was therefore designed to compare in a randomized fashion standard imatinib vs. imatinib + interferon alpha (IFN) vs. imatinib + low dose araC vs. imatinib after IFN (for low- and intermediate-risk patients) or vs. imatinib 800 mg (for high-risk patients). Inclusion criteria were newly diagnosed BCR/ABL positive CML in chronic phase. In July 2005, randomization to the arms imatinib + araC and imatinib after IFN was discontinued and recruitment for imatinib 800 mg was expanded to low- and intermediate-risk patients. Primary goals are: rates of hematologic, cytogenetic and molecular remissions, duration of chronic phase, overall survival, adverse events and analysis of subsequent allografting. Since its activation in 7/2002, 1203 patients have been randomized. The current evaluation represents the first of three designed, statistically adjusted interim analyses of 710 patients randomized by the end of 2005 with a followup of at least 2 years. Analysis was according to intention to treat. 666 patients (545 with primary imatinib, 121 with primary IFN) were evaluable for hematologic, 621 for cytogenetic, and 631 for molecular responses. Median age was 53 years, 60% were male, median values were for Hb 12.5 g/dl, WBC 71.2/nl and platelets 384/nl, 35% had low, 53% intermediate and 12% high risk (Euro score). Median observation time was 3.5 years. Median duration of IFN pretreatment was &lt;4 months. At 1 year, the cumulative incidence of complete hematologic remission (CHR) was 82.3% and 74.4%, of major cytogenetic remission (MCR) 65.6% and 40.6%, of complete cytogenetic remission (CCR) 52% and 19.7%, and of major molecular remission (MMR) 33.2% and 4.7% for primary imatinib and IFN therapies, respectively. At 3 years, the cumulative incidence of CHR was 96.4% and 93.8%, of MCR 89.5% and 89.1%, of CCR 85.2% and 78.5%, and of MMR 79% and 63% for primary imatinib and IFN therapies, respectively. 5-year-survival probability of all patients currently exceeds 90% (94% for imatinib-, 91% for IFN-based therapy, Figure 1). Event free survival after two years (no progression, no death, CCR within the first 18 months, no loss of CHR or MCR) was 80.3%. 36 patients died, 51 patients were transplanted in first chronic phase, and 80 patients progressed, 43 of which were switched to alternative treatments (16 to new drugs, 18 to transplantation, 9 received both). Type and severity of adverse events (AE) did not significantly differ from those reported previously. Hematologic AEs (leukopenia, thrombocytopenia) were most frequent in the imatinib 800 mg arm. Nonhematologic AEs (gastrointestinal) were most frequent in the combination arms and with imatinib 800 mg. In no case recruitment had to be changed due to superiority or inferiority of any arm. This applies also to the high dose imatinib arm where earlier response might translate into better survival. In conclusion, this first interim analysis shows favorable survival and long term response rates. Imatinib in combination with, or after, IFN or with low dose araC are feasible and equally safe treatment alternatives. More definite information will be provided by the next interim evaluation after recruitment has been terminated. Figure Figure" @default.
• W2530998614 created "2016-10-21" @default.
• W2530998614 creator A5000852530 @default.
• W2530998614 creator A5013024565 @default.
• W2530998614 creator A5017002895 @default.
• W2530998614 creator A5019572077 @default.
• W2530998614 creator A5021480569 @default.
• W2530998614 creator A5026106615 @default.
• W2530998614 creator A5031540176 @default.
• W2530998614 creator A5035964802 @default.
• W2530998614 creator A5040985262 @default.
• W2530998614 creator A5052479430 @default.
• W2530998614 creator A5066994665 @default.
• W2530998614 creator A5067841095 @default.
• W2530998614 creator A5069437715 @default.
• W2530998614 creator A5071375810 @default.
• W2530998614 creator A5072582820 @default.
• W2530998614 creator A5076276301 @default.
• W2530998614 creator A5079605019 @default.
• W2530998614 creator A5079652157 @default.
• W2530998614 creator A5084862920 @default.
• W2530998614 creator A5086462994 @default.
• W2530998614 creator A5087994379 @default.
• W2530998614 creator A5088450042 @default.
• W2530998614 creator A5091397639 @default.
• W2530998614 date "2008-11-16" @default.
• W2530998614 modified "2023-10-01" @default.
• W2530998614 title "Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV" @default.
• W2530998614 doi "https://doi.org/10.1182/blood.v112.11.184.184" @default.
• W2530998614 hasPublicationYear "2008" @default.
• W2530998614 type Work @default.
• W2530998614 sameAs 2530998614 @default.
• W2530998614 citedByCount "8" @default.
• W2530998614 countsByYear W25309986142012 @default.
• W2530998614 countsByYear W25309986142013 @default.
• W2530998614 countsByYear W25309986142018 @default.
• W2530998614 crossrefType "journal-article" @default.
• W2530998614 hasAuthorship W2530998614A5000852530 @default.
• W2530998614 hasAuthorship W2530998614A5013024565 @default.
• W2530998614 hasAuthorship W2530998614A5017002895 @default.
• W2530998614 hasAuthorship W2530998614A5019572077 @default.
• W2530998614 hasAuthorship W2530998614A5021480569 @default.
• W2530998614 hasAuthorship W2530998614A5026106615 @default.
• W2530998614 hasAuthorship W2530998614A5031540176 @default.
• W2530998614 hasAuthorship W2530998614A5035964802 @default.
• W2530998614 hasAuthorship W2530998614A5040985262 @default.
• W2530998614 hasAuthorship W2530998614A5052479430 @default.
• W2530998614 hasAuthorship W2530998614A5066994665 @default.
• W2530998614 hasAuthorship W2530998614A5067841095 @default.
• W2530998614 hasAuthorship W2530998614A5069437715 @default.
• W2530998614 hasAuthorship W2530998614A5071375810 @default.
• W2530998614 hasAuthorship W2530998614A5072582820 @default.
• W2530998614 hasAuthorship W2530998614A5076276301 @default.
• W2530998614 hasAuthorship W2530998614A5079605019 @default.
• W2530998614 hasAuthorship W2530998614A5079652157 @default.
• W2530998614 hasAuthorship W2530998614A5084862920 @default.
• W2530998614 hasAuthorship W2530998614A5086462994 @default.
• W2530998614 hasAuthorship W2530998614A5087994379 @default.
• W2530998614 hasAuthorship W2530998614A5088450042 @default.
• W2530998614 hasAuthorship W2530998614A5091397639 @default.
• W2530998614 hasConcept C126322002 @default.
• W2530998614 hasConcept C141071460 @default.
• W2530998614 hasConcept C143998085 @default.
• W2530998614 hasConcept C168563851 @default.
• W2530998614 hasConcept C197934379 @default.
• W2530998614 hasConcept C204243189 @default.
• W2530998614 hasConcept C2777583451 @default.
• W2530998614 hasConcept C2778729363 @default.
• W2530998614 hasConcept C3019892230 @default.
• W2530998614 hasConcept C61943457 @default.
• W2530998614 hasConcept C71924100 @default.
• W2530998614 hasConcept C90924648 @default.
• W2530998614 hasConceptScore W2530998614C126322002 @default.
• W2530998614 hasConceptScore W2530998614C141071460 @default.
• W2530998614 hasConceptScore W2530998614C143998085 @default.
• W2530998614 hasConceptScore W2530998614C168563851 @default.
• W2530998614 hasConceptScore W2530998614C197934379 @default.
• W2530998614 hasConceptScore W2530998614C204243189 @default.
• W2530998614 hasConceptScore W2530998614C2777583451 @default.
• W2530998614 hasConceptScore W2530998614C2778729363 @default.
• W2530998614 hasConceptScore W2530998614C3019892230 @default.
• W2530998614 hasConceptScore W2530998614C61943457 @default.
• W2530998614 hasConceptScore W2530998614C71924100 @default.
• W2530998614 hasConceptScore W2530998614C90924648 @default.
• W2530998614 hasLocation W25309986141 @default.
• W2530998614 hasOpenAccess W2530998614 @default.
• W2530998614 hasPrimaryLocation W25309986141 @default.
• W2530998614 hasRelatedWork W1510481903 @default.
• W2530998614 hasRelatedWork W2080060037 @default.
• W2530998614 hasRelatedWork W2085342571 @default.
• W2530998614 hasRelatedWork W2107268345 @default.
• W2530998614 hasRelatedWork W2151486690 @default.
• W2530998614 hasRelatedWork W2153801741 @default.
• W2530998614 hasRelatedWork W2158884958 @default.
• W2530998614 hasRelatedWork W2485410755 @default.
• W2530998614 hasRelatedWork W2531788586 @default.
• W2530998614 hasRelatedWork W2546964842 @default.
• W2530998614 hasRelatedWork W2549207213 @default.
• W2530998614 hasRelatedWork W2565606062 @default.
• W2530998614 hasRelatedWork W2566047800 @default.

• next